Condition: Ischemic Stroke · Sponsor: Longwood Pharmaceuticals (Hangzhou) Co., Ltd.
This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD, and active metabolites of LWP779 after oral administration in healthy participants.
This description comes directly from the study's public registry record.
Tingting Yan · +86 15989276332 · tingting.yan1@longwoodtech.com
Always discuss trial participation with your own doctor first.
| CMAX Clinical Research Pty Ltd | Adelaide, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07371455